Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind”

December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind.” The report can be accessed here.

Vivos is a commercial stage medtech device and services company focused on the treatment of dentofacial abnormalities and associated conditions, including obstructive sleep apnea (OSA), snoring, and temporomandibular joint dysfunction (TMD). The company’s proprietary Complete Airway Repositioning and/or Expansion (CARE) devices are the first and only oral appliances with FDA 510(K) clearance to treat moderate to severe OSA in adults and children, in addition to the initial clearance for mild to moderate OSA in adults. Vivos provides an end- to-end therapeutic solution for OSA, including diagnostic and screening tools, oral appliances, myofunctional therapy, clinical treatment, continuing education, and practice management software utilizing the Vivos Method proprietary protocol. The product portfolio also includes Guided Growth and Development oral appliances for proper mouth and jaw development in children and Lifeline oral appliances for mild to moderate OSA by mandibular advancement or TMD symptoms, teeth grinding, migraine headaches, and facial muscle pain. Vivos’ oral appliances have treated more than 47,000 patients by more than 2,000 Vivos-trained dentists.

Vivos recently received FDA clearance for the DNA appliance, its flagship CARE device, in pediatric patients aged 6-17 years with moderate/severe OSA. The company believes the FDA clearance is the first ever granted for a medical device therapy in this young OSA population. As the DNA oral appliance is the only non-surgical FDA-cleared medical device approved for pediatric OSA, with clear clinical study-based evidence, Vivos is in a position to provide first- line therapy to the estimated 10.1 million US children (ages 6-17), potentially doubling the market opportunity for the proprietary CARE devices. Of the 47,000 patients treated with Vivos’ oral appliances, more than 20,000 children have used Vivos’ Guided Growth and Development appliances, highlighting the company’s experience in the pediatric space.

About Water Tower Research

Water Tower Research is modernizing Investor Relations through research-driven communications and Investor Engagement. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]